Partnership potential Xanodyne's late-stage pain programs and the menorrhagia NDA readiness create attractive licensing and co-promotion opportunities for larger pharma to accelerate market access.

Targeted markets A focused portfolio in women's health and pain provides clear sales channels with OB/GYNs, pain clinics, and prenatal care networks; prioritize outreach to these specialties.

Flexible collaborations As a small, agile firm with development and commercial capabilities, Xanodyne can be positioned for faster deals, flexible terms, and less integration risk for partners.

Distribution strategy Leverage specialty distributors and hospital/pharmacy networks to maximize reach for Zipsor and pipeline products; also consider cross-selling prenatal vitamins to established OB/GYN channels.

Payer readiness Advance payer engagement and reimbursement strategies ahead of any NDA approval to secure favorable coverage and pricing once products launch.